Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 62.27
(-1.16%)
CNY 62.27
(-1.16%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 886.42 Million CNY | 61.82% |
| 2022 | 547.79 Million CNY | 145.03% |
| 2021 | 223.56 Million CNY | 368.66% |
| 2020 | 47.7 Million CNY | -20.49% |
| 2019 | 60 Million CNY | 1225.92% |
| 2018 | 4.52 Million CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 998.82 Million CNY | 12.68% |
| 2024 Q2 | 961.06 Million CNY | -3.78% |
| 2024 Q3 | 882.21 Million CNY | -5.13% |
| 2023 Q4 | 886.42 Million CNY | 4.06% |
| 2023 Q2 | 753.45 Million CNY | 14.5% |
| 2023 FY | 886.42 Million CNY | 61.82% |
| 2023 Q1 | 658.03 Million CNY | 20.12% |
| 2023 Q3 | 851.83 Million CNY | 13.06% |
| 2022 Q3 | 454.85 Million CNY | 40.04% |
| 2022 Q4 | 547.79 Million CNY | 20.43% |
| 2022 Q2 | 324.8 Million CNY | 8.19% |
| 2022 Q1 | 300.23 Million CNY | 34.29% |
| 2022 FY | 547.79 Million CNY | 145.03% |
| 2021 FY | 223.56 Million CNY | 368.66% |
| 2021 Q1 | 82.57 Million CNY | 73.1% |
| 2021 Q4 | 223.56 Million CNY | 7.32% |
| 2021 Q3 | 208.31 Million CNY | 23.27% |
| 2021 Q2 | 168.99 Million CNY | 104.66% |
| 2020 Q1 | 4.9 Million CNY | -91.82% |
| 2020 FY | 47.7 Million CNY | -20.49% |
| 2020 Q3 | 12 Million CNY | 187.05% |
| 2020 Q2 | 4.18 Million CNY | -14.84% |
| 2020 Q4 | 47.7 Million CNY | 297.53% |
| 2019 Q1 | 20 Million CNY | 341.97% |
| 2019 Q2 | 20 Million CNY | 0.0% |
| 2019 Q3 | 20 Million CNY | 0.0% |
| 2019 Q4 | 60 Million CNY | 200.0% |
| 2019 FY | 60 Million CNY | 1225.92% |
| 2018 FY | 4.52 Million CNY | 0.0% |
| 2018 Q4 | 4.52 Million CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |